Mark Rubinstein to Animals
This is a "connection" page, showing publications Mark Rubinstein has written about Animals.
Connection Strength
0.707
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
Score: 0.045
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.045
-
Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
Score: 0.042
-
IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
Score: 0.038
-
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Ra Dependent. Cancer Immunol Res. 2015 Dec; 3(12):1364-74.
Score: 0.038
-
IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells. Cancer Gene Ther. 2015 Jul; 22(7):360-7.
Score: 0.038
-
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
Score: 0.037
-
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
Score: 0.033
-
Soluble IL-15/IL-15Ra complexes in human serum. Blood. 2012 Jul 05; 120(1):1-2.
Score: 0.030
-
Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
Score: 0.030
-
IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Blood. 2008 Nov 01; 112(9):3704-12.
Score: 0.023
-
Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther. 2009 Feb; 16(2):171-83.
Score: 0.023
-
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9166-71.
Score: 0.020
-
Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003 Feb 01; 170(3):1209-17.
Score: 0.016
-
Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model. PLoS One. 2022; 17(9):e0273076.
Score: 0.015
-
B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
Score: 0.015
-
Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101.
Score: 0.014
-
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol. 2020 09; 50(9):1386-1399.
Score: 0.013
-
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?. Sci Transl Med. 2020 01 08; 12(525).
Score: 0.013
-
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.
Score: 0.012
-
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. J Biol Chem. 2019 06 07; 294(23):9198-9212.
Score: 0.012
-
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
Score: 0.012
-
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. J Biol Chem. 2016 Nov 11; 291(46):23869-23881.
Score: 0.010
-
Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
Score: 0.010
-
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
Score: 0.010
-
Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
Score: 0.010
-
Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
Score: 0.009
-
The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
Score: 0.009
-
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15; 73(10):3075-86.
Score: 0.008
-
Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A. 2010 Dec 14; 107(50):21647-52.
Score: 0.007
-
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010 Oct 01; 70(19):7465-75.
Score: 0.007
-
Surviving the crash: transitioning from effector to memory CD8+ T cell. Semin Immunol. 2009 Apr; 21(2):92-8.
Score: 0.006
-
The lymphopenic environment of CD132 (common gamma-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol. 2008 Apr 15; 180(8):5320-6.
Score: 0.006
-
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008 Apr 15; 68(8):2972-83.
Score: 0.006
-
An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med. 2007 Aug 06; 204(8):1787-801.
Score: 0.005
-
Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med. 2007 Apr 16; 204(4):951-61.
Score: 0.005
-
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
Score: 0.005
-
Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res. 2006 Sep; 26(9):593-608.
Score: 0.005
-
Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. Eur J Immunol. 2006 Aug; 36(8):1994-2002.
Score: 0.005
-
Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006 Mar 31; 311(5769):1924-7.
Score: 0.005
-
Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
Score: 0.004
-
Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
Score: 0.004
-
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003 Mar 01; 170(5):2582-9.
Score: 0.004